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 Abstract 
Objective: To determine the age-specific incidence and clinical-epidemiological 
characteristics of an Amyotrophic lateral sclerosis (ALS) cohort patient in Catalonia 
(Spain). Methods and results: New cases diagnosed between January 1, 2004 and 
December 31, 2013 were 41 (20 men and 21 women), with an annual crude incidence 
rate of 2.7 per 100,000 person-years (95% CI 1.90 – 3.59). The incidence rate 
increased with age reaching a peak in the age-group of 70 to 79 years. There was a 
non significant decrease in the incidence rate in the group of patients over 80 (P value 
= 0.75) 17.99 per 100 000 person years (95% CI 7.81 – 28.17). The percentage of 
patients over age 80 was 29.3% and over age 85 was 9.8%. The prevalence rate at the 
end of the study period was 8.38/100.000 of the total population. Mean age at symptom 
onset was 76.0 years. Onset of symptoms was bulbar or generalized in 36.6% of 
cases. 
Conclusions: ALS incidence in Osona is within the range of other countries across 
Europe. Our results suggest that the age-specific incidence rate of ALS increases with 
age through the oldest age groups suggesting an age-risk effect to develop the 
disease. 
 
Introduction 
Amyotrophic lateral sclerosis (ALS) is a relatively uncommon 
neurodegenerative disorder of unknown aetiology. The disease affects upper and lower 
motor neurons causing rapidly progressive paralysis leading to death due to respiratory 
failure usually within 3 years from symptom onset. 
Because of the low frequency and short survival of people with ALS, large 
numbers of well characterized patients from homogeneous populations within defined 
geographical areas are required to provide detailed epidemiological data to achieve 
conclusions. Prospective, population-based methodology has been shown to be useful 
in defining clinical characteristics and prognostic indicators. Reported incidence rates 
are remarkably uniform across all registries among Caucasian populations, ranging 
from 1.7 to 2.3 cases per 100 000 person-years1-3. 
However, several important epidemiological questions remain unsolved. The 
evidence suggests that ALS risk is probably an age-related condition with a variable 
pattern of susceptibility and a higher risk within a susceptible age group in the late 
sixties or early seventies. Most population-based studies report that the incidence of 
ALS increases with age, reaching a peak around 70 years old but is then followed by a 
decline in frequency in those over 80 years. The whole data suggest that susceptibility 
is lower among the subpopulation of the very elderly1,4-8. However, whether the age-
specific incidence of ALS increases over time through the oldest age groups 
suggesting an age-risk effect, or the incidence decreases among the very elderly 
remains an open question3. 
The decline of incidence rates in those over 75 years has been attributed to 
difficulties with case ascertainment among this particularly fragile group of patients. 
Several reasons have been put forward, such as difficulty in diagnosing ALS among 
the elderly because of comorbidity, difficulty in access to specialised care or a more 
rapid and aggressive disease and shorter survival that cause elderly patients to die 
before the diagnosis of ALS is established3,7,9,10. Identification of subpopulations at risk 
is likely to help to our understanding of the disease pathogenesis. 
With the hypothesis of underdiagnosis of ALS among older people, and to 
counteract the problems in diagnosis in the older age groups, we set up a population 
register of ALS patients using multiple sources of information and prospective 
ascertainment of cases within a very small catchment area. The national health system 
in Catalonia allows free access to medical care meaning that most cases with a 
suspected ALS are assisted by a neurologist at some stage of the disease. 
 
Methodology 
Study area and study population 
The study was conducted in the county of Osona in Central Catalonia, Spain. 
The population of the study area was of 138,630 inhabitants and increased up to 
155,069 during the study period between January 2004 and December 2013 according 
to national census data11. Individuals under the age of 18 were excluded to avoid 
misclassification. Patients were eligible when resident in the study area at least 2 years 
before the date of the diagnosis. 
Case ascertainment 
The Vic University Hospital is the referral centre of the National Health System 
which covers the total population of the study area. The main source of cases was an 
ongoing prospective hospital registry of ALS patients. The registry was set up in 2004, 
and case collection began in January 2004. In addition, we used several sources of 
information to obtain a complete case ascertainment. All neurologists working in the 
public health system, including local hospital and in the ambulatory consultation, within 
the study area were involved in the registry. Rehabilitation and geriatrics departments 
were also contacted and asked to report all possible cases. General practitioners have 
also been invited to ascertain patients with ALS. They have been adequately assessed 
and have received support. One of the neurologist involved in the study periodically 
attended meetings with health care professionals working in primary care and the 
Geriatrics in the study area to discuss and review cases with uncertain diagnosis. 
Archives of the ALS patients’ association were reviewed and ALS experts working in 
regions adjacent and tertiary referral centres and neurologists working in private 
centres were invited to participate in the study. 
Diagnostic criteria 
The diagnosis of ALS was based on the revised version of The El Escorial 
Criteria12. Patients with all forms of motor neuron disease were included, but only 
subjects with criteria for definite, probable or possible ALS were included for the 
analysis of incidence and prevalence data. Patients with progressive muscular atrophy 
and primary lateral sclerosis variants who did not fulfil criteria for ALS during follow up 
were excluded from the analysis. Patients were diagnosed by a consultant neurologist. 
All patients underwent one or more electrophysiological studies; the results were 
reviewed to ensure a clinical diagnosis of ALS. We defined probable familial ALS 
(fALS) when one affected first- or second-degree relative was identified13. 
 
Data management 
A standard form was used to prospectively collect patients’ demographic and 
clinical data and register all eligible patients according to the study protocol. Records 
included place of residence, sex, date of onset and age at time of symptom onset, date 
of diagnosis, and site of onset, recorded as spinal or bulbar. Delay in diagnosis (the 
period of time between onset and diagnosis) and median time of survival from onset of 
the disease were both recorded in months. All the data were submitted and 
anonymized for data analysis to a central office at the Neurology Department of the Vic 
University Hospital. Death certificates of patients with ALS were provided by the Health 
Department of the Government of Catalonia. The study was approved by the Clinical 
research and ethics committee of Vic Hospital Consortium. 
Data analysis 
The prevalence rate was estimated on December 31, 2013 using the number of 
patients with an ALS diagnosis. The denominator for the calculation of prevalence rates 
was the Osona county population in 2013. 
Incidence rates were calculated for the entire study population, for specific age 
groups and by sex. The population of the catchment area older than 18 years was 
considered to be at risk of developing ALS. Age and gender specific incidence rates for 
the study population were calculated from the numbers of new cases identified, divided 
by the combined age and gender specific person-years of observation estimated from 
census data for the geographical region during the period 2004-2013. Crude and 
standardized incidence rates were adjusted using the European population (OMS12) at 
the same period using the direct method OMS14. Ninety-five percent confidence limits 
were calculated assuming a Poisson distribution. For the analysis a P value < 0.05 
(two-sided) was considered statistically significant. 
Descriptive analyses were performed. Categorical variables were described by 
frequencies and percentages. Continuous variables were described by means and 
standard deviations. Relationships between categorical variables were studied using 
the χ2 test and Yates test, and continuous variables were analyzed using Student’s t-
test. The Kaplan-Meier product limit distribution was used for survival analysis. All 
analyses were performed with SPSS for windows Statistics 21. 
Results 
During the study period, between 1 January 2004 and 31 December 2013, 41 
new cases, 20 males (48.8%) and 21 females (51.2%) were diagnosed with ALS. 
Thirteen patients were alive on 31 December 2013, giving a point prevalence of 8.38 
cases per 100,000 of the total population. Mean age at symptom onset was 76.0 years 
for the whole population, ranging from 42 to 89 years, 77.50 years for males and 71.19 
years for females. Onset of symptoms was bulbar in 36.6% of cases with no significant 
differences by age (P value = 0.77) and gender (P value = 0.84). The mean time delay 
from onset to diagnosis was 10.74 ± 6.52 months, shorter in bulbar onset. There were 
no significant differences (P value = 0.75) in the mean time delay to diagnosis between 
patients older than 80 years (1.58 ± 5.23 months) and younger than 80 years (10.81 ± 
7.08 months). 
Ten patients coming from the study area were identified during the study period 
in the registers of the two referral centres for ALS involved in the study. All of them 
have been previously registered within the study area and attended the specialized 
Units looking for an expert opinion on diagnosis. Familial cases represented 7.5% of 
cases. All three fALS cases were in the 70-79 years age group. According to the El 
Escorial revised criteria we classified 90% of cases as definite and 10% as probable 
ALS. Five patients with progressive muscular atrophy and one with primary lateral 
sclerosis variants were excluded. 
The overall annual crude incidence rate was 2.74 per 100 000 person-years 
(95% CI 1.90 – 3.59). The incidence rate in males was 2.67 (95% CI 1.50 – 3.84) and 
in females 2.82 (95% CI 1.61 – 4.03), with a ratio of 0.95. Mean annual incidence 
adjusted by age and gender to the European population was 3.08 (95% CI 2.00 – 
4.17). The age-specific incidence rates of by gender are illustrated in figure 1.The 
incidence rate of ALS increased markedly with increasing age, from none in those aged 
under 30 to 0.30 per 100 000 person years (95% IC 0.0 – 1.15) in the age group of 30 
to 59 years and to 4.73 per 100 000 person years (95% IC 1.04 – 8.43) in the age 
group of 60 a 69 years, reaching 18.22 per 100 000 person years (95% IC 11.17 – 
25.27) in the age group of 70 to 79 years. There was a non significant decrease in the 
incidence rate in the group of patients over 80 (P value = 0.75) 17.99 per 100 000 
person years (95% CI 7.81 – 28.17) (Table 1). The percentage of patients over age 80 
was 29.3% and over age 85 was 9.8%. 
Mean survival time from symptom onset by Kaplan-Meier analysis was 26.62 ± 
3.06 months. There were no gender differences (P value = 0.77) between males (26.43 
± 4.67 months) and females (26.70 ± 4.12 months). Mean survival time by age group 
was 30.91 ± 3.90 months for patients younger than 80 years, significantly longer (P 
value = 0.0009) than for the group of patients older than 80 years (16.83 ± 3.18 
months). There was no significant difference (P value = 0.88) in mean survival time 
between spinal (27.64 ± 3.89) onset forms and bulbar onset forms (24.80 ± 5.25). 
Median survival time from symptom onset was 19.15 ± 3.07 months. Median 
survival time from diagnosis was 9.48 months. 
 
Discussion 
We have conducted a prospective, population-based epidemiological study of 
ALS over a period of 10 years within a small county of Barcelona province, Catalonia, 
Spain, comprising a very stable population. The ultimate objective of the study was to 
determine if the age-specific incidence of ALS increases with age through the oldest 
age groups. The study was carried out within a small, well-defined and restricted 
geographical area with only one referral hospital, during a long time period and using 
secondary sources of case ascertainment to maximise case ascertainment and 
balance the small sample size. 
Our observed incidence rates are within the range of most other previous 
population-based studies using population-based methodology3. We found that 
incidence rates continue to increase with age and the elderly contributed substantially 
to the frequency of ALS; the percentage of patients over age 75 was 55%, being 29.3% 
over age 80 and 9.8% over age 85. 
The body of literature on ALS epidemiology is large but limited geographically15. 
Most research has been conducted in Europe15. 
Our incidence rates are slightly higher than those found in a population-based 
study carried out in the whole territory of Catalonia including the geographical area 
where our study was performed16.  Comparison of incidence of the two studies in the 
people younger than 60 years is difficult because of the extremely low number of 
cases. The differences in the overall annual incidence rates among the two studies can 
be attributed to the higher incidence rates in the subgroups of patients over 70 years 
and are clearly different in the very elderly subgroup of patients aged 80 and over. 
These differences are probably a consequence of the procedures and methods used to 
improve patient capture among elderly onset cases, and the multiple sources of case 
ascertainment used. 
Previous studies have included only a small number of patients over the age of 
80 years. A meta-analysis of published population based registries completed in three 
European countries specifically addressed the need to study age-specific incidences 
over time to distinguish if ALS is a disease of ageing or if there is a decrease in 
incidence among the very elderly3. In that study, incidence rates for the combined 
European cohort increased with advancing age, reaching a peak in the late sixties or 
early seventies, followed by a rapid decline, with 6.6% of patients over age 80 and only 
1.9% over 85 years3. This pattern seems to be consistent across the four published 
European registries10,15. The analysis generated a large number of ALS patients within 
this age group and allowed the authors to conclude there was a true decrease in 
incidence rates among the oldest groups of patients. However, the decrease in 
incidence rates in the population over 75 years of age might in fact still be a result of 
under-ascertainment. Most population based studies show a peak of incidence in the 
65-75 age-group15, only in two studies incidence rates are maintained in the age-group 
over 80 years2,24.  
When large populations are analyzed some cases, such as those patients in 
extreme age groups, can be missed, and the analysis of incidence rates by age might 
be imprecise. A weakness of the study is the small size of the study population, but it is 
extremely stable and has very clearly defined boundaries of the catchment area, 
allowing precise capture of cases17. The study was conducted within a geographical 
area with only one reference hospital, in a national health system which provides free 
access to medical care. Furthermore, the referring physicians have a close working 
relationship with each other, increasing referral rates to the register. This setting 
allowed us to undertake very close surveillance of all incident cases. Using the same 
approach in the same geographical area, we have studied the incidence of other 
neurologic disorders and found the highest reported incidence of myasthenia gravis in 
the elderly18. 
Previous studies have found that fewer than 10% of patients with ALS 
experienced symptom onset over the age of 80 and ALS has been considered 
exceptional over age 85. Only two previous studies have found a proportion of cases of 
people over 80 years above 10%2,24. For example, a recent study in the Limousin 
region in France found higher incidences in the oldest age groups, where ALS 
incidence showed a progressive rise with age culminating in a large peak between 65 
and 85 years19. Although we cannot extrapolate our findings to other populations, when 
taken together with the results from Limousin they suggest that ALS risk may truly 
increase with age, and an increasing incidence will reflect the ageing of populations in 
western countries. Table 2 shows a comparison of age specific incidence rates 
between elderly in Europe. 
The proportion of patients with bulbar-onset ALS in our study (36.6%) was 
higher than the result of the combined analysis of the epidemiological data collected 
from six European ALS registers (30.01%)1. The percentage of bulbar-onset patients is 
also most common than the reported in other studies2,3,11,12,14. As bulbar-onset ALS 
may be more common in the oldest age groups, this difference may be explained by 
the higher proportion of elderly patients in our population. 
Our data supports the notion that motor neuron degeneration may be an 
inevitable part of the ageing process. However, conclusions of the study should be 
considered cautiously because the low numbers of cases registered in our study. 
Previously reported low incidence rates among patients in older age-groups may be 
explained by misdiagnosis of the disease in the group of very old patients. A close 
working relationship and educational interventions among health care professionals in 
primary care service may help to identify patients with suspected motor neuron disease 
and to improve case ascertainment in elderly onset cases.This hypothesis needs to be 
explored and confirmed in future epidemiological studies with larger populations. 
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 Table 1.  
 
Age and gender specific incidence of ALS per 100,000 person-years among those aged 18 
years and over, from the Osona ALS register for the 10 year period 2004-2013. 
 
 Men    Women    Total    
Age 
group 
Cases Person-
years* 
Incidence** 95% 
CI 
Cases Person-
years* 
Incidence** 95% 
CI 
Cases Person 
year* 
Incidence** 95% 
CI 
18-19 0 15369 0.0 0.0-
0.0 
0 14445 0.0 0.0-0.0 0 29814 0.0 0.0-0.0 
20-29 0 100385 0.0 0.0-
0.0 
0 95729 0.0 0.0-0.0 0 196114 0.0 0.0-0.0 
30-39 0 133541 0.0 0.0-
0.0 
0 117024 0.0 0.0-0.0 0 250565 0.0 0.0-0.0 
40-49 0 120147 0.0 0.0-
0.0 
2 110178 1.8 1.7-1.9 2 230325 0.9 0.8-0.9 
50-59 0 93030 0.0 0.0-
0.0 
0 89262 0.0 0.0-0.0 0 182292 0.0 0.0-0.0 
60-69 1 61211 1.6 1.6-
1.6 
5 65606 7.6 7.4-7.8 6 126817 4.7 4.6-4.9 
70-79 12 50197 23.9 23.5-
24.3 
9 65052 13.8 13.6-
14.1 
21 115249 18.2 18.0-
18.4 80-89 7 24929 28.1 23.5-
24.6 
5 41776 12.0 11.7-
12.3 
12 66705 18.0 16.2-
16.8 Total*** 20 749.162 2.7 1.5-
3.8 
21 744.643 2.8 1.6-4.0 41 1.493.805 2,7 1.9-3.6 
Foot legend table 1 
* Osona population 2004-2013 
** Per 100,000 person-years 
*** Total population. 
 
 Table 2. Comparison of age specific incidence rates between elderly in Europe. 
 
Region Years 
Crude 
incidence 
x 100.000 
75-79 
years 
80-84 
years 
≥85 years 
Puglia 
(Italy)1 
1998-
1999 
1.6   0 
Scotland2 1989-
1998 
2.4 
11.3 (9.6-
13.3) 
9.9 (3.2-
7.1) 
 
EURALS 
(Europe)3 
1998-
1999 
2.16 
8.0 (6.7-
9.4) 
5.2 (3.7-
6.6) 
2.5 (1.4-
3.5) 
Catalonia16 1999-
2001 
1.4 
4.7 (3.1-
6.3) 
2.2 (0.8-
3.7) 
0.9 (0-2.8) 
Limousin19 2000-
2011 
3.2 (2.8-
3.6) 
11.5   
South-East 
England20 
2002-
2006 
1.06 
Males 0.9; 
Females 
2.2 
Males 1.4; 
Females 
1.2 
Males 2.1; 
Females 
0.8 
Friuli 
Venezia 
Giulia21 
2002-
2009 
2.72   
3.6 (1.3-
6.0) 
Sardinia22 2005-
2009 
2.5   0 
Rhineland-
Palatinate23 
2010-
2011 
1.8 
2.8 (1.3-
5.3) 
4.5 (2.3-
8.0) 
0.5 (0-2.7) 
Modena24 2000-
2009 
2.9 9.4   
Osona 2004-
2013 
2.74 
19.1 (7.8-
30.4) 
18.4 (5.7-
31.2) 
11.8 (2.4-
23.4) 
 
 Figure 1. 
 
Age-specific incidence rates by gender in the county of Osona in Central Catalonia, Spain 
(January 2004 and December 2013). 
 
 
 
